Contacts
Site Map
Search
Home
Media Room
Lead Product Backgrounder
Product Info: NKTR-061
Product Info: NKTR-061
About Nektar
Our Leadership
Corporate Giving
Locations
Contacts
Pipeline
Pipeline Overview
Nektar Proprietary Products
Nektar Partnered Products
Drug Development Platforms
Partners
Nektar Partners
Investor Relations
Press Releases
Stock Information
Financial Events Calendar
Analyst Coverage
Annual and Financial Reports
Corporate Governance
Investor Contacts
FAQ
Investor Advisory
Media Room
Lead Product Backgrounder
Press Releases
Press Kit
Media Contacts
Information Center
Scientific & Partnering Events
Multimedia
Library
Email Alerts
Careers
Life at Nektar
Career Opportunities
Recruitment Calendar
Summer Internships
Benefits
Recruiting Information
Nektar Employee Foundation
Lead Product Backgrounder
Product Info: NKTR-061
Product Info: NKTR-102
Product Info: NKTR-118
Press Releases
Press Kit
Media Contacts
Press Release:
Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias - August 6, 2007
Press Release:
Nektar Therapeutics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (amikacin inhale) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference - May 21, 2007
Graphic:
Pulmonary Antibiotics Platform
Backgrounder:
Pulmonary Antibiotics Platform
Poster #710:
Amikacin Aerosol Epithelial (ATS Data)
Poster #718:
Reduces Antibiotics (ATS Data)
Poster #719:
Amikacin Aerosol Tracheal (ATS Data)
Poster #720:
Amikacin Aerosol Safe Serum (ATS Data)
Privacy
|
Terms of Use
|
Compliance Policy
|
Trademarks
